The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of pre-existing autoimmune diseases in melanoma patients receiving immune checkpoint inhibition with improved survival and increased toxicity.
 
Nicholas Gulati
No Relationships to Disclose
 
Arda Celen
No Relationships to Disclose
 
Paul Johannet
No Relationships to Disclose
 
Amelia Sawyers
No Relationships to Disclose
 
Min Jae Kim
No Relationships to Disclose
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Sanofi/Regeneron; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; CytomX Therapeutics; Neximmune; Protean Biodiagnostics
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Regeneron; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Protean Biodiagnostics; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Michelle Krogsgaard
Consulting or Advisory Role - Guidepoint Global
Research Funding - F. Hoffmann LaRoche; Merck Sharp & Dohme
 
Iman Osman
No Relationships to Disclose
 
Judy Zhong
No Relationships to Disclose